28/02/2022 – AB Science announces today that it reached an agreement with a historical investor on a financing of USD 8.5 million through the issuance of bonds convertible into new ordinary shares with attached warrants Download PDF Post navigationPreviousPrevious post:AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indicationsNextNext post:Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indicationsRelated PostsPositive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19September 14, 2022AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALSAugust 24, 2022Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and AllergyJune 7, 2022AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALSMay 26, 2022Annual financial results as of 31 December, 2021April 29, 2022Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19April 28, 2022
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19September 14, 2022
AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALSAugust 24, 2022
Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and AllergyJune 7, 2022
AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALSMay 26, 2022
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19April 28, 2022
